Editor: What To Know
- “I look forward to helping Pulmonx continue the important work of bringing minimally invasive solutions to patients suffering from severe emphysema, a form of COPD.
- In addition, Daniel Florin served as Interim Chief Executive Officer of Zimmer Biomet from July 2017 to December 2017.
- “His financial and operating experience will be incredibly beneficial to Pulmonx as we continue our growth in the coming years.
In addition, Daniel Florin served as Interim Chief Executive Officer of Zimmer Biomet from July 2017 to December 2017. Prior to working at Zimmer Biomet, Mr. Florin was Senior Vice President and Chief Financial Officer of Biomet, Inc. until Biomet, Inc. merged with Zimmer, Inc. and became Zimmer Biomet Holdings Inc. Prior to working at Biomet, he held various roles at Boston Scientific Corporation, C.R. Bard Inc. and Deloitte & Touche, LLP.
“I am truly excited to join the Pulmonx board and be part of this experienced team,” said Mr. Florin. “I look forward to helping Pulmonx continue the important work of bringing minimally invasive solutions to patients suffering from severe emphysema, a form of COPD.”
“I am very pleased Dan has agreed to join the Pulmonx Board of Directors,” said Glen French, President, and Chief Executive Officer. “His financial and operating experience will be incredibly beneficial to Pulmonx as we continue our growth in the coming years. I look forward to working with and learning from him.”
